SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

Blood

Volumn 122, Issue 8, 2013, Pages 1455-1463

  Sutherland, May S Kung ^a   Walter, Roland B ^b,c   Jeffrey, Scott C ^a   Burke, Patrick J ^a   Yu, Changpu ^a   Kostner, Heather ^a   Stone, Ivan ^a   Ryan, Maureen C ^a   Sussman, Django ^a   Lyon, Robert P ^a   Zeng, Weiping ^a   Harrington, Kimberly H ^b   Klussman, Kerry ^a   Westendorf, Lori ^a   Meyer, David ^a   Bernstein, Irwin D ^b,c   Senter, Peter D ^a   Benjamin, Dennis R ^a   Drachman, Jonathan G ^a   McEarchern, Julie A ^a  

^a SEATTLE GENETICS INC   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CASPASE 3; CD135 ANTIGEN; CD33 ANTIGEN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CISPLATIN; CYSTEINE; GEMTUZUMAB OZOGAMICIN; HISTONE H2AX; PROTEIN P53; PROTEINASE; PYRROLOBENZODIAZEPINE DIMER; SYNTHETIC DNA; UNCLASSIFIED DRUG; VADASTUXIMAB TALIRINE; ANTIBODY CONJUGATE; BENZODIAZEPINE DERIVATIVE; CROSS LINKING REAGENT; LINTUZUMAB; MONOCLONAL ANTIBODY;

ACUTE MYELOID LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DNA DAMAGE; DRUG CONJUGATION; DRUG EFFECT; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING; XENOTRANSPLANTATION; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL; CELL CYCLE; CELL STRAIN HEK293; CELL STRAIN HL 60; CHEMISTRY; DIMERIZATION; DRUG DESIGN; DRUG RESISTANCE; GENETICS; IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; BENZODIAZEPINES; CELL CYCLE; CROSS-LINKING REAGENTS; CYSTEINE; DIMERIZATION; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HEK293 CELLS; HL-60 CELLS; HUMANS; IMMUNOCONJUGATES; LEUKEMIA, MYELOID, ACUTE; MICE; SIALIC ACID BINDING IG-LIKE LECTIN 3;

EID: 84886825064     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-491506     Document Type: Article

References (31)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1): 10-29.
2. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006; 107(9):3481-3485.
3. Döhner H, Estey EH, Amadori S, et al; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3): 453-474.
4. Estey E, Döhner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894-1907.
5. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997; 89(9):3323-3329.
6. Marie JP, Zittoun R, Sikic BI. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood. 1991;78(3): 586-592.
7. Jilani I, Estey E, Huh Y, et al. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol. 2002;118(4):560-566.
8. Legrand O, Perrot JY, Baudard M, et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood. 2000;96(3):870-877.
9. Cowan AJ, Laszlo GS, Estey EH, Walter RB. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. Front Biosci. 2013;18:1311-1334.
10. Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012;119(26): 6198-6208.
11. Jurcic JG. What happened to anti-CD33 therapy for acute myeloid leukemia? Curr Hematol Malig Rep. 2012;7(1):65-73.
12. Rosenblat TL, McDevitt MR, Mulford DA, et al. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res. 2010;16(21):5303-5311.
13. Fenton C, Perry CM. Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia. Drugs. 2005;65(16):2405-2427.
14. Sievers EL, Larson RA, Stadtmauer EA, et al; Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244-3254.
15. Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012; 30(32):3924-3931.
16. Castaigne S, Pautas C, Terré C, et al; Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825): 1508-1516.
17. Delaunay J, Recher C, Pigneux A, et al. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study [abstract]. Blood. 2011;118(21): 37-38.
18. Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854-4860.
19. Hartley JA, Hochhauser D. Small molecule drugs - optimizing DNA damaging agent-based therapeutics. Curr Opin Pharmacol. 2012;12(4): 398-402.
20. Smellie M, Bose DS, Thompson AS, Jenkins TC, Hartley JA, Thurston DE. Sequence-selective recognition of duplex DNA through covalent interstrand cross-linking: kinetic and molecular modeling studies with pyrrolobenzodiazepine dimers. Biochemistry. 2003;42(27):8232-8239.
21. Wu J, Clingen PH, Spanswick VJ, et al. gamma-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000). Clin Cancer Res. 2013;19(3):721-730.
22. Burke PJ, Jeffrey S, Meyer D, et al. Anti-CD70 antibody-drug conjugates containing pyrrolobenzodiazepine dimers demonstrate robust antitumor activity. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; March 31-April 4, 2012; Chicago, IL. Abstract 4631.
23. Nelson EJ, Zinkin NT, Hinkle PM. Fluorescence methods to assess multidrug resistance in individual cells. Cancer Chemother Pharmacol. 1998;42(4):292-299.
24. Hartley JA, Spanswick VJ, Brooks N, et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Res. 2004;64(18): 6693-6699.
25. Rogakou EP, Nieves-Neira W, Boon C, Pommier Y, Bonner WM. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem. 2000; 275(13):9390-9395.
26. Han Z, Chatterjee D, He DM, et al. Evidence for a G2 checkpoint in p53-independent apoptosis induction by X-irradiation. Mol Cell Biol. 1995; 15(11):5849-5857.
27. Matsui H, Takeshita A, Naito K, et al. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia. 2002;16(5): 813-819.
28. Naito K, Takeshita A, Shigeno K, et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia. 2000;14(8):1436-1443.
29. Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood. 2003;102(4):1466-1473.
30. Tang R, Faussat AM, Perrot JY, et al. Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). BMC Cancer. 2008;8:51.
31. Benderra Z, Faussat AM, Sayada L, et al. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res. 2005;11(21): 7764-7772.